Philippe Camus, M.D.

Dijon, France

Both apps are now back!

Back

The Drug-Induced Respiratory Disease Website and App

Minocycline

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I - Interstitial/parenchymal lung disease

I.a

Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b

Pneumonitis (interstitial lung disease/ILD)
I.c

Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d

Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.e

Acute eosinophilic pneumonia (AEP)
I.k

Lung nodule or nodules
I.l

Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.aj

Shrinking lung syndrome

II - Pulmonary edema - Acute lung injury - ARDS

II.a

Pulmonary edema, noncardiogenic (NCPE)
II.b

ARDS - Acute lung injury

IV - Airway involvement

IV.d

Cough (lone)

V - Pleural and/or pericardial involvement

V.d

Pleural/pericardial effusion, ANA positive (DI lupus)
V.m

Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

VII - Mediastinal involvement

VII.a

Lymphadenopathy (intrathoracic)

X - Systemic/Distant conditions, syndromes and reactions

X.a

DRES syndrome - DRESS-like reaction
X.b

Antiphospholipid antibodies w/wo the APL syndrome
X.d

Lupus - Lupus syndrome (see also Vd)
X.e

Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)
X.f

Anaphylaxis-Anaphylactoid reaction (can be fatal)
X.g

Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)
X.m

Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)
X.o

Neutrophilic dermatosis (Pyoderma, Sweet syndrome)
X.s

Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive
X.v

Systemic eosinophilic syndrome w/wo vasculitis (see also Xa)
X.aj

Polyarteritis nodosa-like condition

XI - Miscellaneous

XI.b

Chest pain (acute or subacute), lone or prominent
XI.c

Pleuritic chest pain

XII - Cardiovascular involvement / toxicity

XII.c

Pericardial effusion (w/wo tamponade)
XII.d

Myocarditis (can be fulminant)
XII.as

Giant cell myocarditis

XV - Pathology

XV.b

Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
XV.d

Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XV.ac

Path: Pulmonary vasculitis other than capillaritis
XV.ad

Path: Eosinophilic vasculitis
XV.af

Path: Granulomatous pulmonary vasculitis
XV.cj

Path: Brownish macrophages in airspaces (airways - alveoli)

XVI - Imaging

XVI.e

Imaging: Pulmonary opacities with a subpleural distribution

XVIII - Distinctive patterns - 'Eye-catchers'

XVIII.y

Eye catcher: Pseudocyanosis

XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.b

BAL: An excess proportion of neutrophils
XIX.c

BAL: An excess proportion of eosinophils